Abstract Submission Deadline: November 18, 2021
Late-Breaking and Clinical Trials Abstract Submission Deadline: January 10, 2022
Continuing Medical Education Activity - AMA PRA Category 1 Credits™ available
# AACR ANNUAL MEETING 2022

AACR.org/AACR2022  #AACR22

## ABOUT THE COVER IMAGE:

*Images, clockwise:*
A cancer survivor in treatment, nanotechnology (purple), a technician in the lab, cancer cell mitosis, tumor evolution (blue/red), a cancer survivor post-treatment, epigenetics (orange/yellow), a young investigator in the lab, animal models (white), a pediatric patient, drug development (green), a researcher in the lab, DNA/human genome (green/orange).

©2021 American Association for Cancer Research

---

## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>AACR Annual Meeting 2022 Key Dates</td>
</tr>
<tr>
<td>5</td>
<td>Welcome</td>
</tr>
<tr>
<td>6</td>
<td>Why You Should Attend</td>
</tr>
<tr>
<td>8</td>
<td>Program</td>
</tr>
<tr>
<td>12</td>
<td>Spotlight on Clinical Trials</td>
</tr>
<tr>
<td>14</td>
<td>Professional Advancement Opportunities</td>
</tr>
<tr>
<td>16</td>
<td>Continuing Medical Education (CME)</td>
</tr>
<tr>
<td>17</td>
<td>Survivor and Patient Advocacy Program</td>
</tr>
<tr>
<td>18</td>
<td>Press Coverage and Social Media</td>
</tr>
<tr>
<td>19</td>
<td>Financial Support for Attendance</td>
</tr>
<tr>
<td>21</td>
<td>Guidelines for Preparation and Submission of Abstracts</td>
</tr>
<tr>
<td>25</td>
<td>Meeting Resources</td>
</tr>
<tr>
<td>27</td>
<td>Abstract Categories</td>
</tr>
<tr>
<td>32</td>
<td>AACR Membership Opportunities</td>
</tr>
<tr>
<td>36</td>
<td>Housing</td>
</tr>
<tr>
<td>38</td>
<td>Travel</td>
</tr>
<tr>
<td>40</td>
<td>General Information</td>
</tr>
<tr>
<td>42</td>
<td>Hotel List</td>
</tr>
<tr>
<td>44</td>
<td>AACR Annual Meeting Committees</td>
</tr>
</tbody>
</table>

---

## AACR Officers

**President**  
David A. Tuveson

**President-Elect**  
Lisa M. Coussens

**Immediate Past President**  
Antoni Ribas

**Treasurer**  
William N. Hait

**Chief Executive Officer**  
Margaret Foti

### Board of Directors

Nina Bhardwaj  
John D. Carpten  
Marcia R. Cruz-Correa  
Luis A. Diaz, Jr.  
Keith T. Flaherty  
Silvia Chiara Formenti  
Elaine Fuchs  
Susan M. Galbraith  
Roy S. Herbst  
Thomas J. Lynch, Jr.  
Ira Mellman  
Lisa A. Newman  
Martine F. Roussel  
Charles Swanton  
Suzanne L. Topalian

---

©2021 American Association for Cancer Research
AACR ANNUAL MEETING 2022 KEY DATES

**September 2021**
- September 14, 2021: Membership Application Deadline for Early Access to Housing Reservations
- September 21, 2021: Abstract Submission Opens
- September 21, 2021: Early Access to Housing Reservations Opens for Members
- September 28, 2021: Housing Reservations Open to Nonmember Attendees
- September 30, 2021: Application Deadline: NextGen Stars

**October 2021**
- October 2021: Meeting Registration Opens

**November 2021**
- November 12, 2021: Membership Application Deadline for Prospective Regular Abstract Sponsors and Scholar-in-Training Award Applicants
- November 18, 2021: Regular Abstract Submission Deadline (11:59 p.m. ET)
- November 18, 2021: Application Deadlines:
  - AACR Global Scholar-in-Training Awards
  - AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Awards
  - AACR Minority Scholar in Cancer Research Awards
  - AACR Scholar-in-Training Awards
  - AACR Undergraduate Scholar Awards
  - AACR Women in Cancer Research Scholar Awards
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
</table>
| **December 2021**  | **December 10, 2021** Membership Application Deadline for Early Registration Rate  
|                    | **December 17, 2021** Early Registration Deadline (lowest rates)     |
|                    | **December 17, 2021** Late-Breaking and Clinical Trials Abstract Submission Opens  |
| **January 2022**   | **January 5, 2022** Membership Application Deadline for Prospective Late-Breaking and Clinical Trials Abstract Sponsors  
|                    | **January 6, 2022** Online Itinerary Planner Available (tentative)  
|                    | **January 10, 2022** Late-Breaking and Clinical Trials Abstract Submission Deadline (11:59 p.m. ET)  
|                    | **January 31, 2022** Regular Abstract Status Notifications Sent  |
| **February 2022**  | **February 3, 2022** Submission Deadline: Final Data for Clinical Trial Placeholder Abstracts  
|                    | **February 9, 2022** Late-Breaking and Clinical Trials Abstract Notifications Sent  
|                    | **February 11, 2022** Abstract Submission Deadline: Undergraduate Student Caucus and Poster Competition  
|                    | **February 11, 2022** Membership Application Deadline for Advance Registration  
|                    | **February 18, 2022** Advance Registration Deadline (discounted rates)  
|                    | **February 21, 2022** Regular Abstract Withdrawal Deadline  
|                    | **February 25, 2022** Housing Reservation Deadline  |
| **March 2022**     | **March 4, 2022** Cancellation Deadline for Registration Refunds (less $125 processing fee)  
|                    | **March 7, 2022** Late-Breaking and Clinical Trials Abstract Withdrawal Deadline  
|                    | **March 8, 2022** Regular Abstract Titles and Texts Posted to Online Itinerary Planner (4:30 p.m. ET)  
|                    | **March 8, 2022** Late-Breaking and Clinical Trials Abstract Titles Posted to Online Itinerary Planner (4:30 p.m. ET); Abstract Texts Embargoed until April 8, 2022  
|                    | **March 18, 2022** AACR Annual Meeting App Available for Download (tentative)  
|                    | **March 18, 2022** Registration Deadline: Undergraduate Student Caucus and Poster Competition  
| **April 2022**     | **April 1, 2022** Membership Application Deadline to Register for the AACR Annual Meeting at the Member Rate On-Site  
|                    | **April 8, 2022** On-Site Registration Opens at New Orleans Ernest N. Morial Convention Center  
|                    | **April 8, 2022** AACR Annual Meeting Begins (12:00 p.m. CT)  
|                    | **April 8, 2022** Late-Breaking and Clinical Trials Abstract Texts Posted to Online Itinerary Planner and Meeting App (no earlier than 1:00 p.m. ET)  

Dear Members and Friends of the AACR,

We are pleased to invite you to attend the AACR Annual Meeting 2022. The meeting will be held April 8-13, 2022, in New Orleans, Louisiana, a vibrant city that brings together the language, music, and cuisine of several cultures to create an exciting and distinctive energy.

Much like New Orleans, the AACR Annual Meeting has its own unique energy, as it brings together scientists, clinicians, other health care professionals, and cancer survivors and patient advocates from across the international cancer research community. That is why we are thrilled to return to an in-person meeting in 2022. While the 2020 and 2021 AACR Annual Meetings demonstrated the value and potential of virtual meetings, nothing will match the palpable excitement and synergies that ensue at an in-person AACR Annual Meeting in New Orleans. As we well know, at the convention center and headquarters hotels, attendees will network, make new connections, forge fruitful collaborations, and discuss the latest advances across the full spectrum of cancer science and medicine.

The theme of this year’s meeting is “Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.” It reflects our focus on the myriad of processes that contribute to cancer development and, in particular, how those processes vary from patient to patient depending on their environment, lifestyle, and germline genetics. Clearly, our concerted goal is to put patients at the center of the meeting’s content, to understand how diversity and disparities across populations affect their outcomes, and to bring our best science to bear on transforming those outcomes.

We are deeply grateful to the Program Committee Vice Chairs and Cochairs for accepting the challenge of developing an outstanding scientific, multidisciplinary program. The Opening Plenary Session will address the theme of the meeting and set the tone for a week of cutting-edge science. Daily plenary sessions will explore vital areas such as precancer discovery science, immunotherapy, decoding cancer health disparities, and tumor evolution and therapeutic resistance. Experts from around the world will present the latest discoveries from across the continuum of basic, translational, clinical, prevention, and population research, as well as regulatory science and public policy.

This spectacular program will be preceded by a comprehensive educational program with content that will appeal to all registrants. Beginning at 3:00 p.m. on Friday, April 8, and running through Saturday, April 9, a multitude of educational sessions and methods workshops will introduce attendees to innovative, emerging scientific and clinical concepts and new technologies across a wide range of disciplines.

The invited program will be supplemented by a robust slate of proffered papers, and we encourage you and your colleagues to submit your abstracts by the November 18, 2021 deadline to be considered for oral presentations in Minisymposia or for poster presentations. We strongly recommend that all presenters of proffered papers, irrespective of the format, present their work in person; however, the meeting will offer enhanced virtual presentation opportunities for those who are unable to join us in New Orleans.

The proffered program will also feature special oral presentation opportunities for abstracts reporting results of high-impact clinical trials. These presentations will be enjoyed by clinical and translational scientists as well as members of the media, who will be reporting on these new data to all constituencies, including members of the public. We encourage all clinical trialists to consider the AACR Annual Meeting as a preferred presentation forum for their work. The deadline for clinical trials abstracts is January 10, 2022.

The AACR Annual Meeting program will also showcase the work of promising early-career and early-stage scientists. All AACR Associate Members as well as Active Members at the assistant professor level or equivalent are invited to apply to the NextGen Stars program, which offers oral presentation slots in major sessions to applicants presenting highly meritorious research. To be considered for this exciting opportunity, interested members must submit an application and extended abstract by September 30, 2021.

We look forward to our first in-person AACR Annual Meeting since 2019. This year’s meeting will mark an even more significant milestone in the history of our organization—the 115th anniversary of the founding of the AACR in 1907. Throughout the meeting we will be celebrating the rich history of progress in cancer research along with the AACR’s pivotal role at the forefront of all the major advances against cancer. For your interest and enjoyment, a special program acknowledging our anniversary will be held during the Opening Ceremony on Sunday morning, April 10.

We trust that you will join us in New Orleans to celebrate the return to our in-person AACR Annual Meetings, the AACR’s 115th anniversary, and especially the research progress against cancer to which you have personally contributed that saves, extends, and enhances the lives of cancer patients. Please check the AACR website (AACR.org/AACR2022) regularly for program updates and announcements. We look forward to receiving your abstract submissions and to welcoming you to the AACR Annual Meeting in April 2022.

With very best wishes and regards,

David A. Tuveson, MD, PhD, FAACR
President, 2021-2022

Marcia R. Cruz-Correa, MD, PhD
Chair, 2022 Program Committee
Why You Should Attend the World’s Most Important Cancer Research Meeting

The AACR Annual Meeting highlights the work of the greatest minds in cancer science and medicine from institutions all over the world. This meeting presents the many scientific discoveries across the breadth of cancer research—from prevention, early detection, and interception; to cancer biology and genetics, translational, and clinical studies; to survivorship, population science, and advocacy. You will be exposed to the latest developments in all areas of cancer research, form new collaborations, and learn how to apply exciting new concepts, tools, and techniques to your own research.

This year’s program, with the theme of “Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes,” will be a comprehensive, cutting-edge scientific event that you will not want to miss!

The AACR Annual Meeting 2022 Will Highlight:

- **Pre-Annual Meeting Sessions**—A number of Educational Sessions and Methods Workshops will once again be offered beginning on Friday, April 8.
- **Clinical Trials**—Included in the growing science-based clinical research program at the AACR Annual Meeting, clinical trials will once again be a part of Clinical Trials Plenary Sessions, Minisymposia, and Poster Sessions.
- **NextGen Stars Program**—The NextGen Stars oral presentations will showcase early-career scientists who are AACR Associate Members and early-career Active Members up to the level of assistant professor or equivalent. To apply, submit your abstract and supporting materials by September 30, 2021. Details can be found at [AACR.org/AACR2022](http://AACR.org/AACR2022).
- **Wrap-Up Plenary Session**—The meeting will close with key opinion leaders presenting the most exciting highlights from the meeting and providing visionary remarks about cancer research opportunities in the future. The Wrap-Up Plenary Session will be on Wednesday, April 13, 12:15 p.m.-1:30 p.m.
- **Advances in the Science of Cancer Health Disparities**—The Science of Cancer Health Disparities will once again be featured during these special sessions in 2022.
Why You Should Submit an Abstract

The AACR Annual Meeting is the premier event for presenting the cutting-edge cancer science that is shaping the future of cancer research and delivering cures to patients. Every abstract that is accepted for publication in the online Proceedings of the AACR is presented at the AACR Annual Meeting as a proffered paper, and all abstracts are considered for oral presentation in Minisymposia.

Opportunities to give an oral presentation and simultaneously publish your work in a high-impact AACR journal are available for abstract submissions. See page 23 for more details.

AACR’s 115th Anniversary

Join us in New Orleans as we kick off a year-long commemoration of the AACR’s leadership in cancer science and medicine over the past 115 years. We are marking this milestone with a series of special programs under the theme “The Driving Force to Eradicate Cancer.” Anniversary events during the AACR Annual Meeting will include an exciting video and live presentation that celebrates AACR’s pivotal role at the forefront of the major advances against cancer and takes a bold look into the future of the field. In addition, special distinguished public service awards will recognize key contributions in support of the AACR’s mission. Further, an updated “Landmarks in Cancer Research” pavilion in the convention center will celebrate the rich history of cancer research, with a special focus on the breakthroughs of the past five years and commentaries from thought leaders on new frontiers for the cancer research community.
Beginning at 3:00 p.m. on Friday, April 8, and continuing all day Saturday, April 9, 2022, a program of Educational Sessions and Methods Workshops will be presented. The program on Saturday will conclude with the Precancer Discovery Science Plenary Session. The Opening Ceremony and the Opening Plenary Session will take place on Sunday morning, April 10. The meeting will conclude at 1:30 p.m. on Wednesday, April 13. The 2022 Program in Progress follows:

**Educational Program: Educational Sessions and Methods Workshops**

The Educational Program is an integral part of the meeting and provides attendees with an opportunity to expand their knowledge base. The Educational Program consists of more than 70 unique sessions covering all areas of cancer research, including the popular multisession programs noted below. More information about the Educational Program will be available at AACR.org/AACR2022.

- **Tumor Immunology and Immunotherapy for Nonimmunologists.** Annually, this two-part series combines a comprehensive review of a hot topic in the field with a networking session that enables attendees to participate in group discussions with leading experts in the field.

- **Chemistry to the Clinic.** This three-part series provides attendees with foundational knowledge of critical elements of the drug development process, such as lead optimization, identification of targets, and drug modalities.

- **Clinical Trial Design.** Over the course of three consecutive sessions, this Methods Workshop will provide attendees with a historical and methodologic understanding of clinical trials and demonstrate how to design an appropriate trial to answer the scientific questions presented by emerging treatments.

Additional details will be posted at AACR.org/AACR2022.
Plenary Sessions
Saturday, April 9, 2022
Precancer Discovery Science
Chair: Catriona H.M. Jamieson, UCSD Moores Cancer Center, La Jolla, CA
Avrum E. Spira, Johnson & Johnson and Boston University Medical Center, Boston, MA
Rebecca Fitzgerald, Hutchison/MRC Research Center, Cambridge, United Kingdom
Veronica Kinzler, The Francis Crick Institute, London, United Kingdom
Susan M. Domchek, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Sunday, April 10, 2022
Opening Plenary Session: Decoding Cancer Complexity, Integrating Science, Transforming Patient Outcomes
Chair: Marcia R. Cruz-Correa, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR
Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
James M. Crawford, Yale University, West Haven, CT
Marcia C. Haigis, Harvard Medical School, Boston, MA
Nickolas Papadopoulos, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Franziska Michor, Dana-Farber Cancer Institute, Boston, MA
Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY

Monday, April 11, 2022
Decoding Cancer Health Disparities: Integration of Complex Data and Diversity to Achieve Equity
Chair: Mariana C. Stern, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Yu Shyr, Vanderbilt University Medical Center, Nashville, TN
Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA
Olusegun I. Alatise, Obafemi Awolowo University, Ile-Ife, Nigeria
Andy Futreal, The University of Texas MD Anderson Cancer Center, Houston, TX
Cheryl L. Willman, Mayo Clinic Comprehensive Cancer Center, Rochester, MN; and University of New Mexico Comprehensive Cancer Center, Albuquerque, NM

Tuesday, April 12, 2022
Precision Medicine for Immuno-ontology and the Promise for the Future
Chair: Carl H. June, University of Pennsylvania, Philadelphia, PA
Ton N. Schumacher, Netherlands Cancer Institute, Haarlem, The Netherlands
Thomas F. Gajewski, University of Chicago, Chicago, IL
Luis A. Diaz, Memorial Sloan Kettering Cancer Center, New York, NY
Shannon J. Turley, Genentech, Inc., South San Francisco, CA

Wednesday, April 13, 2022
Tumor Evolution and Therapeutic Resistance
Chair: Anna D. Barker, Ellison Institute for Transformative Medicine, Los Angeles, CA
Emmanuelle Passegué, Columbia University Irving Medical Center, New York, NY
Peter J. Campbell, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, TX
Charles Swanton, The Francis Crick Institute, London, United Kingdom

AACR Annual Meeting 2022 Highlights: Vision for the Future
Chair and speakers to be announced
Major Symposia
Adipose Tissue as a Driver of Carcinogenesis
Aging and the Tumor Microenvironment’s Impact on Minimal Residual Disease and Cancer Recurrence
Artificial Intelligence in Cancer Research and Care
Bone Metastasis
Cancer Evolution Biomarkers
Cancer Stem Cell Metabolism, Proteostasis, and Metastasis
Cancer Vaccines: New Developments and Clinical Response
Challenging Drug Targets
Clinical Progress with CD3 Bispecifics
Digital and Computational Histopathology: Taking Cancer Diagnostics to the Cutting Edge
Epigenetic Alterations as Cancer Therapeutic Targets
Epigenome Biology and Cancer
Extracellular Matrix Remodeling in Cancer
Extrachromosomal DNA: Origins and Significance
Genome Instability as a Driver of Cancer Evolution
Germline Mutations as Drug Targets
Identification of Cancer Dependencies
Immunoprevention and Clinical Trials
Immunotherapy for Solid Tumors and Blood Cancers in Adult and Pediatric Patients
Liquid Biopsy: From Discovery to Clinical Application
Macroenvironmental and Microenvironmental Drivers of Cancer Stem Cell Generation
Mechanisms of Cancer Stem Cell Immune Evasion
Mechanisms of Protein Degradation Chemistries for Cancer Therapy
Mechanisms of Structural Mutations in Cancer
Metabolism of the Tumor Microenvironment
Metastatic Organotropism
Microdosing and Drug Delivery
Modern Synthetic Lethality Strategies in Targeting the DNA Damage Response and Beyond: Moving beyond PARP and BRCA
Multiomics Approaches for Novel Oncopathogen Discovery and Related Mechanisms
Myeloid Targets to Enhance Therapeutic Antitumor Immunity
Nerves, Cancer, and Immunity
Novel Genetic Screening Strategies to Identify Therapeutic Targets in Cancer
Novel Mechanisms for Targeting KRAS
Pathophysiology and New Treatments for Cancer-Associated Thrombosis
Physical Aspects of Cancer and Physical Sciences of Oncology
Predictive Biomarkers for Precision Radiation Oncology
Profiling Molecular Proximity in Cancer Research
Radiation and Immunotherapy
The Science of Survivorship
Screening, Detecting, Intervening Earlier in Clinical Care of Underserved Populations
Targeting Noncancer Syndromes with Cancer Drugs
The Crossroads between Epigenetic Regulation and Metabolism in Cancer
Tumor Dormancy
Understanding Microbe-Tumor Interactions in Health and Disease: From Basic Mechanisms to Applied Microbial-Based Cancer Therapy

Advances in Organ Site Research
Advances in Bladder Cancer
Advances in Glioblastoma Cancer Research and Cancer Care
Advances in Neuroblastoma Research
Advances in Ovarian Cancer Screening and Treatment
Bone Marrow Immune Microenvironment
Breast Cancer Genomics in Latin America
Gastric Cancer: From Biology to Therapy
Models for Rare Cancers
New Targets for Prostate Cancer
Pediatric Tumors
Advances in Organ Site Research

Progress in Understanding Nonalcoholic Fatty Liver Disease-Induced Liver Cancer and Associated Disparities
Triple Negative Breast Cancer: Molecular Insights and Treatment Advances
Understanding Microbe–Tumor Relationships in Colorectal Cancer

Science and Public Policy Program

Decisions made by policy makers in Washington, DC, have a direct impact on cancer research and the progress being made against cancer in the United States and throughout the world. The AACR sponsors sessions with policy makers, academic researchers, patient advocates, cancer survivors, and industry representatives to foster dialogue about emerging topics in science and health policy, and regulatory science and policy.

The Science and Health Policy Track includes sessions that will provide attendees with an opportunity to learn about how policy impacts science and vice versa. Science policy sessions will examine the current political environment affecting federal funding for the NIH and NCI, including highlighting ways for scientists to get involved in advocating for robust, sustained, and predictable budget increases.

Health policy sessions will explore how scientific evidence can inform policy on cancer prevention and control and what impact policies are having on patients and communities. Past health policy sessions have covered topics such as e-cigarettes and tobacco control measures, the Affordable Care Act, and ways to prevent and control pathogen-related cancers, such as increasing the use of the human papillomavirus (HPV) vaccine.

The Regulatory Science and Policy Track includes informative sessions designed to highlight recent regulatory developments and provide an open forum for the consideration of issues that the FDA faces as the agency seeks to accelerate the pace of approval of safe and effective treatments for patients with cancer. These sessions offer an opportunity for attendees to discuss cutting-edge issues in cancer drug, biologic, and diagnostic regulation with stakeholders from academia, industry, advocacy, and government. Past regulatory science and policy topics have included strategies for increasing participation of underrepresented populations in clinical trials, guidance for using real-world evidence to support clinical trials during the COVID-19 pandemic, regulatory considerations for developing liquid biopsy tests, implications of site-agnostic therapy approval for drug development, and applications for artificial intelligence/machine learning in regulatory decision-making.

The Science of Survivorship Track includes sessions highlighting new and high-value areas of research to address the array of challenges facing long-term cancer survivors. Sessions invite transsector discussion among the survivor and advocacy communities, basic and clinical researchers, industry representatives, health care providers, and government officials. Past science of survivorship topics have included aging and cancer, long-term survivorship and vulnerable populations, development of new survivorship models, patient-reported outcomes, data sharing, and patient engagement.
Submit Your Clinical Trials Abstracts to the AACR Annual Meeting 2022

Become a part of our growing science-based clinical research program at the AACR Annual Meeting and help us showcase how research continues to transform the lives of cancer patients.

Why You Should Submit

• Numerous and unique oral presentation opportunities including:
  - Four Clinical Trials Plenary Sessions offering companion presentations discussing the science behind the trials presented
  - Three Clinical Trials Minisymposia
• Poster presentations
• Opportunities for extensive national media coverage through the AACR press program
• Opportunities to publish a manuscript in a high-impact AACR journal, including possible simultaneous publication with your abstract presentation

What to Submit

• Any phase (I, II, III, or any combination) abstract from national or international clinical trials
• Trials for solid tumors or blood cancers in adult and pediatric patients
• Promising ongoing trials, or unique trial designs that have not yet yielded results. Select the Clinical Trials in Progress category (CT08).
• Encore clinical trials presentations that have been presented solely in abstract form, including publication in conference proceedings. Submissions must include significant additional data from the previous presentation (as determined by the AACR Clinical Trials Committee).
• See page 30 for clinical trials (CT) abstract categories and visit AACR.org/AACR2022 for submission guidelines.

- Indicate your intention to submit a manuscript related to your abstract during the abstract submission process
- Contact aacrpublisher@aacr.org with any questions
- No restrictions on presenters if the presentation is CME-compliant
When to Submit

- Submit your completed or placeholder abstract(s) by the January 10, 2022 deadline for clinical trials and late-breaking abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the November 18, 2021 deadline.

- Final results and conclusions for placeholder abstracts are due by February 3, 2022.

---

**AACR Annual Meeting 2021**

38  
CLINICAL TRIALS ABSTRACTS PRESENTED IN PLENARY SESSIONS AND MINISYMPOSIA

86  
CLINICAL TRIALS ABSTRACTS PRESENTED IN POSTER SESSIONS

49  
CLINICAL TRIALS IN PROGRESS ABSTRACTS PRESENTED IN POSTER SESSIONS

173  
TOTAL CLINICAL TRIALS ABSTRACTS PRESENTED
In support of the mission to promote the education and training of cancer scientists and clinicians, and to cultivate a highly skilled and diverse cancer research workforce, the AACR provides AACR Annual Meeting attendees at all career stages—from high school and undergraduate students to senior investigators—with opportunities to advance their careers. For more information about any of the professional development opportunities that follow, visit AACR.org/AACR2022 and click on the “Professional Development Opportunities” tab.

**NextGen Stars**

Early-career scientists can apply to give a presentation in a Major Symposium or Advances Session at the AACR Annual Meeting 2022. Speaking slots are limited and are only available to AACR Associate Members and to AACR Active Members who are not above the level of assistant professor or equivalent. The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career scientists at the AACR Annual Meeting and to support their professional development and advancement.

The deadline to submit applications is 5:00 p.m. U.S. ET, September 30, 2021. Applications consist of an extended abstract (limit 8,000 characters), a CV, and a letter of recommendation from a P.I., department head, or another mentor who is familiar with the applicant’s work. Applicants selected as NextGen Stars for 2022 will receive travel support and complimentary registration for the meeting. Details can be found at AACR.org/AACR2022 under the “NextGen Stars” tab.

**Professional Advancement Series Sessions**

**Exclusive Member Benefit**

Professional Advancement Sessions have long been an integral part of the AACR Annual Meeting experience, representing the AACR’s dedication to the education, training, and career advancement of cancer research investigators at all stages of their careers. A collaborative effort each year by the AACR Science Education and Career Advancement Committee, Minorities in Cancer Research (MICR) Council, Women in Cancer Research (WICR) Council, and Associate Member Council (AMC), provides several interactive and engaging professional development and career advancement opportunities to educate investigators at all levels, including students, early-career scientists, and early-stage investigators.
All Professional Advancement Sessions are free and exclusive to AACR members. There is no cost to join the AACR as an Associate Member (graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to a career in cancer research) or Student Member (undergraduate and high school students). If you are not an AACR member, you are strongly encouraged to join the AACR and take advantage of the opportunity to attend these sessions and the many other benefits of membership, including the privilege of sponsoring abstracts, significantly reduced member registration rates, and more. Visit AACR.org/Membership to apply today!

Professional Advancement Sessions to be held at the Annual Meeting 2022 will be announced in the fall. Visit AACR.org/PAS to learn more and for session updates.

“I particularly enjoyed the breakout sessions during the Professional Advancement Sessions; they were inspirational and motivational too.”
The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Accreditation with Commendation status by the Accreditation Council for Continuing Medical Education (ACCME). The AACR CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advancing the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. The AACR Annual Meeting 2022 will be a Continuing Medical Education Activity and *AMA PRA Category 1 Credits™* will be available. This is a great opportunity to complete your required credit hours.

**Meet Your MOC Point Requirements**

If you are a physician, you can meet your Maintenance of Certification (MOC) point requirements at the AACR Annual Meeting 2022. The meeting is CME/MOC accredited. Successful completion of the CME activity enables you to earn MOC points of the American Board of Internal Medicine’s (ABIM) Maintenance of Certification program.
AACR’s Commitment to Cancer Survivors and Patient Advocates

The voices of patients with cancer have never been more important than in today’s environment, especially as patients are partnering with researchers by selflessly donating tissue and personal data to advance progress. Additionally, patient advocates play a crucial role in educating the public about new research discoveries, serving on committees and panels to guide cancer research and regulatory policies, increasing awareness among legislators, and raising precious funds for cancer research.

The AACR recognizes and celebrates the contributions of survivors and patient advocates to cancer research and policy and welcomes their attendance and participation at the AACR Annual Meeting. Advocate Affiliate Members in good standing are offered free registration to the AACR Annual Meeting. The AACR Membership Application Form is available on the AACR website at AACR.org/Membership.

Discounted registration rates are available for nonmember patient advocates.

AACR Scientist↔Survivor Program®

Now in its 24th year, the AACR Scientist↔Survivor Program® (SSP) is an annual special education program for patient advocates.

Led admirably since its inception by Anna D. Barker, PhD, FAACR, of the Lawrence J. Ellison Institute for Transformative Medicine of USC, SSP is designed to build enduring partnerships among the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide. The program has a competitive application process which will open in October 2021.

This unique program provides an opportunity for patient advocates to learn about cancer research and to interact with scientists, physicians, health care professionals, and other advocates.

Specifically, patient advocate representatives come together to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research areas in the cancer field. Advocates benefit from special scientific lectures; stimulating small group discussions; and other opportunities to exchange information on key aspects of cancer research, survivorship, advocacy, and public policy.

If you are interested in applying for this year’s SSP, please visit AACR.org/SSP2022 or email advocacy@aacr.org.

Patient advocates can also engage with the AACR in many ways throughout the year, including through virtual AACR Patient Advocate Forums, AACR’s magazine Cancer Today, the AACR Foundation, the annual AACR Cancer Progress Report(s), and advocacy days on Capitol Hill. To learn more visit AACR.org/patient-advocacy.
Attracting Journalists Worldwide, Generating Major News Coverage

The AACR is the authoritative resource and voice for cancer research, and the AACR Annual Meeting garners the best in national and international news coverage. The AACR Annual Meeting 2021, held virtually in April and May, attracted a total of 206 registered reporters. The meeting showcased innovative clinical, translational, and basic research and generated more than 2,100 media clips in leading consumer and trade outlets including The Associated Press, CNN, Reuters, and STAT, among many others.

All abstracts accepted for presentation at the meeting will be considered for inclusion in the official AACR Annual Meeting 2022 press program. For more information on the AACR Annual Meeting press program, please contact Julia Gunther at julia.gunther@aacr.org or Rick Buck at rick.buck@aacr.org.

Utilizing Social Media to Amplify the Conversation

The AACR Annual Meeting 2021 also generated significant social media activity in the cancer research community. Social media highlights included:

- 4,500+ people joining the conversation on Twitter
- 18,300 total tweets using the #AACR21 hashtag
- 147,500,000 total impressions
Through the generosity of its loyal supporters and grants from the National Cancer Institute (NCI), the AACR is pleased to provide financial support to meritorious undergraduate students and early-career scientists residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Detailed information about these award programs, including eligibility and selection criteria is available below.

**AACR Scholar-in-Training Awards**

**Exclusive Member Benefit**

Scholar-in-Training Awards are available for Associate Members in good standing who are the presenters of meritorious proffered papers at the AACR Annual Meeting. These awards are made possible by the generosity of supporting foundations and corporations. Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a Scholar-in-Training Award should submit their AACR membership applications by **November 12, 2021**. The AACR Membership Application Form is available on the AACR website at [AACR.org/Membership](http://AACR.org/Membership). To apply for a Scholar-in-Training Award, an applicant must first submit an abstract, and then complete a separate award application. For details of the application process and the selection criteria, please visit [AACR.org/SITA](http://AACR.org/SITA). Application deadline: **November 18, 2021**.

**AACR Global Scholar-in-Training Award**

Global Scholar-in-Training Awards (GSITA) of $2,000 are available for eligible early-career investigators in countries building cancer research capacities. Applicants must submit an abstract to the AACR Annual Meeting 2022 and then complete a separate GSITA application. Applicants must be Associate Members of the AACR in good standing (membership current through 2021). Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a GSITA should submit a Membership Application Form by **November 12, 2021**, before submitting their GSITA application. For additional details and a list of eligible countries, visit [AACR.org/GSITA](http://AACR.org/GSITA). Application deadline: **November 18, 2021**.
AACR-Minorities in Cancer Research (MICR)-Sponsored Awards

AACR Minority and Minority-Serving Institution Faculty (MMSIF) Scholar in Cancer Research Awards

Full-time underrepresented minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other post-secondary institutions as defined by the U.S. Department of Education) who present a proffered paper at this conference are encouraged to apply for this meritorious scholar award for travel.

Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the NCI, these awards are intended to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. Only citizens of the United States or Canada, or scientists who are permanent residents of these countries, may receive one of these awards. For details or to submit an application, visit AACR.org/MSI. Application deadline: November 18, 2021.

AACR Minority Scholar in Cancer Research Awards

Presenters of proffered papers who are full-time predoctoral (graduate or medical) students, residents, and clinical or postdoctoral fellows who are engaged in cancer research or have the training and potential to make contributions to this field are encouraged to apply for this meritorious scholar award. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the NCI, this program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research, e.g., African American/Black, Alaskan Native, Hispanic/Latino, Native American, and Native Pacific Islander. Only citizens of the United States or Canada, or scientists who are permanent residents of these countries, may receive one of these awards. For details or to submit an application, visit AACR.org/MSA. Application deadline: November 18, 2021.

AACR-Women in Cancer Research (WICR) Scholar Awards

The AACR-Women in Cancer Research (WICR) Scholar Award is a highly competitive award recognizing WICR members who are scientists-in-training and presenters of meritorious scientific papers at the AACR Annual Meeting. The purpose of this award is to increase the scientific knowledge base of WICR members and to encourage them to pursue careers in cancer research. Eligible candidates encouraged to apply include AACR-WICR members who are graduate students, medical students, residents, clinical fellows, and postdoctoral fellows. Nonmembers are encouraged to join. For details or to apply, visit AACR.org/WSA. Application deadline: November 18, 2021.

AACR Undergraduate Scholar Awards

In keeping with the AACR’s efforts to promote the education and training of the next generation of committed scientists, the AACR is pleased to provide AACR Undergraduate Scholar Awards. This award program is highly competitive and intended to inspire young, third-year science students to enter the field of cancer research and to provide a unique educational opportunity for these students in the development of their careers in science. Selected students will receive scholar awards to participate in two consecutive AACR Annual Meetings. To learn more about this award program, visit AACR.org/UndergradAwards. Application deadline: November 18, 2021.
Poster Presentation Format

Because some AACR Annual Meeting attendees and presenters may be restricted from traveling to New Orleans in April 2022, the AACR Annual Meeting 2022 will offer the following options for presenters of abstracts accepted for poster presentation:

• **In-Person Presentation with E-Poster**—Presenters are strongly encouraged to travel to New Orleans to present their posters in person. However, all in-person presenters will also be required to submit a companion e-poster presentation to accommodate registered attendees who are unable to attend the meeting in person.

• **E-Poster Only**—Presenters of accepted posters who are unable to travel to New Orleans will be required to submit an e-poster. These presenters will be expected to be available remotely during the dates of the poster sessions (April 10-13) to respond to any questions submitted through the e-poster platform.

**PLEASE NOTE:** E-poster presenters who do not attend the meeting in person are still required to register for the meeting.

E-posters will only be available to registered AACR Annual Meeting attendees. E-poster formats and submission instructions will be provided to presenters of accepted posters with their acceptance notifications in January 2022. Online-only posters will be placed in separate sessions.

During the abstract submission process you will be asked to indicate your current presentation intentions in the event that your abstract is accepted for poster presentation. You will have the option to change your preference once acceptance notifications are sent out in January 2022.

**AACR Abstract Submission System**

Authors must submit abstracts for presentation at the AACR Annual Meeting 2022 using the AACR Abstract Submission System, which will be available at [AACR.org/AACR2022](http://AACR.org/AACR2022) beginning September 21, 2021. You can create, modify, and submit abstracts until the November 18, 2021, abstract deadline. Complete instructions on the use of the AACR Abstract Submission System will be provided on the website.

**NOTE FOR 2022:** Submit your abstract detailing how you use AACR Project GENIE data by the November 18, 2021, deadline for an opportunity to be featured in a special session during the AACR Annual Meeting 2022. Simply include GENIE as a keyword during the submission process.
The Abstract Submission System has been optimized for the current versions of most browsers. Browsers should be set to enable JavaScript and to accept cookies. Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 or aacr@support.ctimeetingtech.com.

Responsibilities of Authors

By submitting an abstract for presentation at the AACR Annual Meeting, abstract authors agree and/or attest to the following:

• **Support for Abstract/Verification of Authorship.** All authors accept individual responsibility for the accuracy and integrity of statements in their abstract, and the submitting author is required to ensure that all authors have confirmed that all statements are an accurate reflection of the presented data and have agreed to the submission of the abstract and to their being listed as contributors prior to submission. Authors will be notified of their inclusion on an abstract via e-mail.

• **Sponsorship of Abstracts.** The submitting author must provide the name of an AACR member who has agreed to sponsor the abstract, and the submitting author must attest that the permission of the member sponsor has been secured prior to initiating an abstract submission. See page 24 for Abstract Sponsorship Regulations.

• **Transfer of Copyright.** On behalf of all authors, the submitting author must assign and transfer copyright for the abstract to the AACR.

• **Presentation of Abstracts.** The submitting author for each abstract must designate a presenter who agrees to register for the meeting and attend the corresponding session to discuss in detail the research presented in the published abstract. If the assigned presenter cannot attend the meeting, the authors are expected to designate a replacement or withdraw the abstract (see pages 21-22).

• **Confirmation of No Prior Publication/Presentation.** Authors who submit an abstract confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2022.

EXCEPTION: Encore presentations are permitted for clinical trials abstracts that are submitted for the January 10, 2022, clinical trials deadline. During the submission process, authors of encore clinical trials abstracts must provide the date and name of the meeting at which the original trial abstract was presented.

Content of Abstracts

Each abstract should contain (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to *Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition* (Council of Science Editors, 2014).

Abstract Control Number

An Abstract Control Number (e.g., 22-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

Financial Relationships of Coauthors

Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships of each of your coauthors. For more information on financial relationships, visit AACR.org/CME.

Sponsor Permission and Information

Each abstract must be sponsored by an AACR member. You must secure the permission of the sponsor before submitting the abstract. For details, see the “Abstract Sponsorship Regulations” on page 24.

Length of Abstracts

The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.
Abstract Category, Subcategory, and Subclassification

You must select a category, subcategory, and subclassification for your abstract. See pages 27-31 for details.

Disclosure of Chemical Structures

At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids co-crystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required.

The Program Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts without chemical structures may be accepted for presentation if deemed to be of sufficient scientific merit.

Submission Fee

Each abstract submitted must be accompanied by a US$75 abstract submission fee. The submission fee can be paid by credit card or check. The fee is nonrefundable regardless of the final disposition of the abstract.

Abstract Deadline

The deadline for abstract submissions is 11:59 p.m. U.S. ET, Thursday, November 18, 2021. Abstracts submitted after the deadline will not be considered by the Program Committee. No significant changes may be made to abstracts after the November 18, 2021 deadline.

NOTE: Submitting an abstract for presentation at the AACR Annual Meeting 2022 does not constitute registration for the meeting. Abstract presenters must register to attend the meeting at AACR.org/AACR2022.

GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS (cont’d)

Late-Breaking Abstract Deadline

The deadline for late-breaking abstracts is 11:59 p.m. U.S. ET, Monday, January 10, 2022. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific priority will be accepted.

Abstract submission fees and sponsorship regulations also apply to late-breaking abstracts.

Clinical Trials Abstract Deadline

All abstracts describing clinical trials (including placeholder abstracts) should be submitted as late-breaking abstracts (see page 8). The deadline for clinical trials abstracts is 11:59 p.m. U.S. ET, Monday, January 10, 2022. Final data for placeholder abstracts are due Thursday, February 3, 2022. Abstract submission fees and sponsorship regulations also apply to clinical trials abstracts.

Publication Opportunities

Authors who intend to submit a manuscript based on their abstract for publication in an AACR journal can be considered for simultaneous publication of the manuscript and presentation of the abstract. In addition, manuscripts can be considered for publication beyond the simultaneous opportunity. For more information on all publication opportunities in an AACR journal, please contact the AACR Publishing Division at aacrpublications@aacr.org.

Presentation of Proffered Papers at the AACR Annual Meeting

Every proffered abstract that has been accepted for publication in the online Proceedings must have a corresponding presentation at the meeting. Specifically, the author listed as the presenter for an accepted proffered paper must attend the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the paper, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no abstract authors are available to present the data, the presenter must withdraw the abstract immediately by contacting the AACR Program Development Department at 215-440-9300 or abstractchanges@aacr.org.
Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:

- The withdrawal of the abstract from the session
- The removal of the abstract from the online *Proceedings*
- The loss of future sponsorship privileges for the sponsor of the abstract
- The loss of future abstract submission/authorship privileges for the presenter of the abstract

**Deadline for Withdrawal of Abstracts**

Requests to withdraw regular abstracts will be accepted through **Monday, February 21, 2022**. Requests to withdraw late-breaking or clinical trials abstracts will be accepted through **Monday, March 7, 2022**. Withdrawal requests must be sent by email to abstractchanges@aacr.org. Withdrawal requests must include the Abstract Control Number and title as well as an explanation of the reason for withdrawal.

**Abstract Sponsorship Regulations**

**Expanded Abstract Sponsorship Privileges for AACR Members**

Expanded abstract sponsorship privileges for selected AACR member types are available for the AACR Annual Meeting 2022, as outlined below:

- **Active, Honorary, and Emeritus Members** may now sponsor an unlimited number of abstracts for presentation at the meeting. (As always, members must verify the content, authenticity, and quality of the abstracts they agree to sponsor.)

- **Affiliate Members** are permitted to sponsor one abstract for each deadline provided that they are the presenter of the abstract. Affiliate Members are **not required to provide an endorser** for their abstract.

Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the November 18 regular abstract deadline, member dues must be paid in full through 2021. To be in good standing for the January 10 late-breaking and clinical trials abstract deadline, member dues must be paid in full through 2022. Associate, Honorary, and Emeritus Members are exempt from the payment of dues; therefore, this regulation does not apply to them.

1. Each abstract submitted for presentation at the AACR Annual Meeting must be sponsored by an Active, Emeritus, Honorary, Affiliate, or Associate AACR Member in good standing (dues paid or eligibility recertified). (Student members are not eligible to sponsor an abstract.)

2. An Active, Emeritus, or Honorary Member may sponsor an unlimited number of abstracts and may use his or her sponsorship privileges in two ways: (a) to sponsor abstracts on which he or she is listed as an author, or (b) to sponsor abstracts submitted by colleagues on which he or she is not listed as an author.

3. An Associate Member in good standing may sponsor one abstract for each submission deadline provided that (a) he or she is the presenter of the abstract, and (b) an Active, Emeritus, or Honorary Member in good standing endorses the work. Active, Emeritus, and Honorary Members may endorse an unlimited number of abstracts.

4. An Affiliate Member in good standing may sponsor one abstract for each submission deadline provided that he or she is the presenter of the abstract. (Affiliate Members are not required to provide an endorser.)

5. Permission to list an AACR member as a sponsor or endorser must be obtained prior to selecting the sponsor/endorser in the Online Abstract Submission System. Individuals listed as sponsors or endorsers of abstracts will receive a notification of sponsorship or endorsement via email.

6. The sponsor must verify the content, authenticity, and quality of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

**Membership Application Deadlines for Abstract Sponsorship**

Nonmember individuals interested in joining the AACR and sponsoring an abstract for AACR Annual Meeting 2022 must submit an application for membership no later than **November 12, 2021**. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than **January 5, 2022**. Membership questions may be directed to membership@aacr.org.
AACR Annual Meeting Program/Navigation

AACR Annual Meeting attendees can use the following electronic and print resources to plan their itineraries and navigate the meeting:

- **Online Itinerary Planner (available January 6, 2022).** Search all AACR Annual Meeting presentations (including all proffered abstracts beginning March 8, 2022) by author/speaker, title word, and keyword and create a personal itinerary for the meeting. Personal itineraries created in the Itinerary Planner can be exported as an iCalendar file into attendees’ personal Outlook, Google Calendar, or Apple iCal applications. Itineraries can also be imported into the AACR Annual Meeting App (see below).

- **AACR Annual Meeting App (available March 18, 2022).** Attendees can carry the AACR Annual Meeting wherever they go—with or without a network connection. The AACR Annual Meeting App is available in native versions to serve users of iPhone, iPad, and Android devices and also in a browser-based version for use on most web-enabled smartphones and tablets. Once downloaded, all App content and functionality is stored locally on the user’s Apple or Android device and can be accessed without an Internet connection—including the full text of more than 6,000 abstracts. Users can search, browse, and select sessions to create a personal itinerary for the meeting. They can also import their itineraries from the Online Itinerary Planner (see above).

- **Print Program Guide.** All attendees receive a portable Program Guide containing the dates, times, locations, and titles of all AACR Annual Meeting sessions. The Program Guide also contains the names of the chairs and invited speakers in each session as well as the titles of all invited presentations. More detailed program information (including the Minisymposium and Poster Session presentations) is available in the electronic versions of the program (see above).

- **Print Guide to Poster Sessions and Exhibits.** Detailed information on the Poster Sessions (including the complete titles and authors of the posters presented) and the Exhibit Show is available in this print guide. A limited number of copies of the guide are made available in the Registration Area and in the Exhibit Hall for attendees to pick up. Complete Poster Session information is also available in the electronic versions of the program (see above).
AACR Annual Meeting Abstracts

The following electronic and print resources are available to attendees who wish to access the proffered abstracts accepted for presentation at the AACR Annual Meeting:

- **Online Proceedings/Itinerary Planner (abstracts available March 8, 2022).** The Online Proceedings/Itinerary Planner provides fully searchable access to the full text of all proffered abstracts (see above).

- **AACR Annual Meeting App (available March 18, 2022).** The full text of all proffered abstracts is stored natively in the AACR Annual Meeting App (see above).

- **Mobile Proceedings (March 23, 2022).** The mobile edition of the Proceedings of the AACR Annual Meetings contains the full text of all regular proffered abstracts as well as the extended abstracts submitted by invited speakers (clinical trial and late-breaking abstracts are not included). The mobile edition is available in mobi and e-pub file formats for download to devices such as the Amazon Kindle, iPad, iPhone, iPod Touch, Sony Reader, and the Barnes & Noble Nook.

- **Online Supplement to Cancer Research (available June 2022).** Approximately eight weeks after the AACR Annual Meeting, all presented abstracts are published as an online-only supplement to the AACR journal Cancer Research.

Please Note: Due to declining demand, the print Proceedings will no longer be offered for purchase to AACR Annual Meeting attendees.
The AACR Annual Meeting 2022 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the AACR Annual Meeting 2022. Please note that these abstract categories may or may not be used as AACR Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is November 18, 2021 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is January 10, 2022 (11:59 p.m. ET).

The AACR is committed to raising awareness about the enormous public health challenge of cancer health disparities and racial inequities. We encourage you to view the relevant abstract subcategories and subclassifications in the listing below. Also, the submission category, COVID-19 and Cancer, provides an opportunity to submit novel work in this timely and critically important area.
MCB01  Cell Growth Signaling Pathways
Cell signaling
Cell-cell interactions
Growth factors
GTPases, their regulators, and effectors
Kinases and phosphatases
Receptors
Tumor-stromal cell interactions
Ubiquitin and ubiquitin-like proteins
Other

MCB02  Cell Death
Apoptosis
Autophagy
Bcl-2 family proteins
Caspases
Effectors of apoptosis
Inhibitor of apoptosis (IAP) family proteins
Necrosis and necroptosis
Transcriptional control of apoptosis
Other

MCB03  Oncogenes and Tumor Suppressor Genes
Cytoplasmic signal transducers
Genotype/phenotype correlations
Nuclear oncoproteins and tumor suppressor genes
Oncogene growth factors and their receptors
Tumor suppressor genes
Other

MCB04  Gene Regulation and Transcription Factors
Chromatin structure and function
Gene expression
Mechanisms of transcription
Onco/normal transcription factors
Posttranscriptional and translational control
Promoters and enhancers of transcription
Protein-protein interactions in transcription factor function
Regulation of transcription factor function
Transcriptional control of cell differentiation
Other

MCB05  Epigenetics and Epigenomics
Chromatin structure and function
DNA methylation
Epigenetic changes as molecular markers of cancer
Epigenomics
Gene silencing
Histone modification
Other

MCB06  Cell Cycle
CDKs and CDK inhibitors
Cell cycle checkpoints
Control of cell cycle progression
Telomeres and telomerase
Other

MCB07  DNA Damage and Repair
Chromosomal structural alterations/translocations
Genomic instability
Homologous recombination
Mechanisms of genomic alterations
Radiation-induced DNA damage
Other

MCB08  Metabolism and Cancer
Metabolic pathways
Metabolomics
Mitochondrial function
Signaling pathways that regulate metabolism
Other

MCB09  Genomics
(See also BCS01: Bioinformatics and Computational Biology)
Functional genomics
Genomic profiling of tumors
High-throughput sequencing
Large-scale approaches to cancer gene discovery
Microarrays
Other

MCB10  microRNAs and Other Noncoding RNAs
Epigenetic control of miRNA expression
miRNA profiling in cancer
miRNA regulation of cancer biology
miRNA-based diagnostics
miRNA-based Therapeutics
miRNAs as tumor suppressors/oncogenes
Noncoding RNAs
Other

MCB11  Cellular Stress Responses
Hypoxia
Oxidative stress
Premature cellular aging
Senescence
Unfolded protein response
Other

BCS  Bioinformatics, Convergence Science, and Systems Biology

BCS01  Bioinformatics and Computational Biology
(See also MCB09: Genomics)
Analytic pipeline optimization
Application of bioinformatics to cancer biology
Database resources
Molecular modeling
New algorithms
New software tools for data analysis
Sequence analysis
Statistical methods
Other

BCS02  Convergence Science and Systems Biology
Artificial intelligence and machine/deep learning
Digital pathology and artificial intelligence
Integrative cancer science
Mathematical modeling
Network biology
Physical sciences in oncology
Systems engineering
Other

TB  Tumor Biology

TB01  Nonclinical Models of Cancer
3-D and tissue recombinant models
Developmental phenotypes of cancer genes
Human-in-mouse models of human cancer
Model organisms in drug discovery
Mouse models of human cancer
Noninvasive imaging in animal models
Organoids
Patient-derived xenograft models
Zebrafish models of cancer
Other animal and cell models of cancer
Other

TB02  Stem Cell Biology
Adult stem cells
Cancer stem cells
Developmental pathways in cancer
Embryonic stem cells
Stem cell markers
Stem cells and regenerative medicine in oncology
Other

TB03  Tumor Adhesion
Cell adhesion and extracellular matrix
Cell-cell adhesion
Drug resistance
Other

TB04  Metastasis
Actin cytoskeleton
Biomarkers of metastasis
Epithelial/mesenchymal transition (EMT and MET)
Expression profiling of tumor progression and metastasis
Genes that regulate migration and invasion
Imaging of tumor progression and metastasis
Invasion and migration
Metastasis suppressor genes
Metastasis-promoting genes
Premetastatic niche
Therapeutic metastasis prevention
Other

TB05  Angiogenesis
Angiogenesis and angiogenesis inhibitors
Host-tumor interactions
Molecular mechanisms of angiogenesis
Novel pro- and antiangiogenic factors
Tumor microcirculation and the microenvironment
Other

TB06  Tumor Microenvironment
Chemokines in the microenvironment
Drug targets in the microenvironment
Extracellular matrix and integrins
Gene expression in the microenvironment
Immune cells in the tumor microenvironment
Inflammatory cells as regulators of tumor growth
Microbiome
Organ-specific microenvironments
Proteases and inhibitors in the microenvironment
Tumor dormancy
Tumor/stromal interactions
Tumor-immune system interactions
Other

TB07  In Vivo Imaging
(See also CLO1: Translational Research – Molecular Biology in Clinical Oncology)
Advanced nanotechnology and imaging
Application of imaging technology to the clinic
Imaging in animal models
Imaging of molecular and cellular events in the tumor microenvironment
Imaging of molecular and cellular events in tumors and tumor cells
Imaging the immune response
Imaging tumor metabolism
New targets for imaging
Other
## ABSTRACT CATEGORIES (cont’d)

<table>
<thead>
<tr>
<th>TB08</th>
<th>Pediatric Cancer - Basic Science</th>
</tr>
</thead>
<tbody>
<tr>
<td>(See also CL02: Pediatric Cancer - Clinical Investigations; CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer) Developmental origins and drivers of pediatric cancer</td>
<td></td>
</tr>
<tr>
<td>Pediatric cancer genetics and epigenomics</td>
<td></td>
</tr>
<tr>
<td>Pediatric cancer models</td>
<td></td>
</tr>
<tr>
<td>Pediatric cancer tumor microenvironment and tumor heterogeneity</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TB09</th>
<th>Radiation Science</th>
</tr>
</thead>
<tbody>
<tr>
<td>(See also CL07: Radiation Oncology; ET09: Preclinical Radiotherapeutics)</td>
<td></td>
</tr>
<tr>
<td>Modulators of radiation response</td>
<td></td>
</tr>
<tr>
<td>Photobiology/photodynamic therapy</td>
<td></td>
</tr>
<tr>
<td>Radiation dose fractionation</td>
<td></td>
</tr>
<tr>
<td>Radiation-activated signaling pathways</td>
<td></td>
</tr>
<tr>
<td>Radiation-induced gene expression</td>
<td></td>
</tr>
<tr>
<td>Radiation-induced resistance</td>
<td></td>
</tr>
<tr>
<td>Radiobiology research</td>
<td></td>
</tr>
<tr>
<td>Radioprotectors and radiosensitizers</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TB10</th>
<th>Tumor Evolution and Heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Causes and consequences of tumor heterogeneity</td>
<td></td>
</tr>
<tr>
<td>Clonal evolution</td>
<td></td>
</tr>
<tr>
<td>Complex adaptive systems</td>
<td></td>
</tr>
<tr>
<td>Methods to measure tumor evolution and heterogeneity</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TB11</th>
<th>Carcinogenesis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical, environmental, and virus-induced carcinogenesis</td>
<td></td>
</tr>
<tr>
<td>Mutagenesis</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CH</th>
<th>Chemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH01</td>
<td>Drug Discovery, Design, and Delivery</td>
</tr>
<tr>
<td>Basic and applied nanotechnology and therapeutics</td>
<td></td>
</tr>
<tr>
<td>Chemoinformatics, in silico screening, and computational methods</td>
<td></td>
</tr>
<tr>
<td>Drug delivery</td>
<td></td>
</tr>
<tr>
<td>Drug design</td>
<td></td>
</tr>
<tr>
<td>High-throughput screening (assays and libraries)</td>
<td></td>
</tr>
<tr>
<td>Lead identification</td>
<td></td>
</tr>
<tr>
<td>Lead optimization</td>
<td></td>
</tr>
<tr>
<td>Nanotechnology drug delivery</td>
<td></td>
</tr>
<tr>
<td>Natural products</td>
<td></td>
</tr>
<tr>
<td>Synthesis, metabolism, and disposition</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CH02</th>
<th>Structural and Chemical Biology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical genetics and genomics</td>
<td></td>
</tr>
<tr>
<td>Nanotechnology in chemical biology</td>
<td></td>
</tr>
<tr>
<td>Small molecule, protein, and nucleic acid interactions</td>
<td></td>
</tr>
<tr>
<td>Target identification, small molecule probes, and libraries</td>
<td></td>
</tr>
<tr>
<td>X-ray and NMR structures</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CH03</th>
<th>Proteomics and Mass Spectrometry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biological mass spectrometry and systems biology</td>
<td></td>
</tr>
<tr>
<td>Proteomics and biomarker discovery</td>
<td></td>
</tr>
<tr>
<td>Proteomics and signaling networks</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ET</th>
<th>Experimental and Molecular Therapeutics</th>
</tr>
</thead>
<tbody>
<tr>
<td>ET01</td>
<td>Drug Discovery</td>
</tr>
<tr>
<td>Antibody technologies</td>
<td></td>
</tr>
<tr>
<td>Biochemical modulators of the therapeutic index</td>
<td></td>
</tr>
<tr>
<td>Combination chemotherapy</td>
<td></td>
</tr>
<tr>
<td>Differentiation therapy</td>
<td></td>
</tr>
<tr>
<td>New targets</td>
<td></td>
</tr>
<tr>
<td>Novel assay technology</td>
<td></td>
</tr>
<tr>
<td>Novel drug delivery systems</td>
<td></td>
</tr>
<tr>
<td>Targeting the tumor microenvironment in drug development</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ET02</th>
<th>Mechanisms of Drug Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell cycle mechanisms of anticancer drug action</td>
<td></td>
</tr>
<tr>
<td>Cellular responses to anticancer drugs</td>
<td></td>
</tr>
<tr>
<td>Interactions of new agents with radiation and the tumor microenvironment</td>
<td></td>
</tr>
<tr>
<td>Role of the therapeutic response</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ET03</th>
<th>Drug Resistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug resistance in molecular targeted therapies</td>
<td></td>
</tr>
<tr>
<td>Drug transport and metabolism</td>
<td></td>
</tr>
<tr>
<td>Novel mechanisms</td>
<td></td>
</tr>
<tr>
<td>Regulation of gene expression in drug resistance</td>
<td></td>
</tr>
<tr>
<td>Reversal of drug resistance</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ET04</th>
<th>Molecular Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell death pathways and treatment</td>
<td></td>
</tr>
<tr>
<td>DNA damage response</td>
<td></td>
</tr>
<tr>
<td>Identification of molecular targets</td>
<td></td>
</tr>
<tr>
<td>Modulation of DNA repair</td>
<td></td>
</tr>
<tr>
<td>Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes</td>
<td></td>
</tr>
<tr>
<td>New nonclinical models for targets</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ET05</th>
<th>Pharmacology, Pharmacogenomics, and Pharmacogenomics</th>
</tr>
</thead>
<tbody>
<tr>
<td>(See also CT01: Phase I Adult Clinical Trials)</td>
<td></td>
</tr>
<tr>
<td>Cellular pharmacology</td>
<td></td>
</tr>
<tr>
<td>Molecular pharmacology</td>
<td></td>
</tr>
<tr>
<td>Pharmacogenetics and therapeutic response</td>
<td></td>
</tr>
<tr>
<td>Pharmacogenomics</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics and pharmacodynamics</td>
<td></td>
</tr>
<tr>
<td>Preclinical toxicology</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ET06</th>
<th>Small Molecule Therapeutic Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA-reactive agents</td>
<td></td>
</tr>
<tr>
<td>Epigenetic targets</td>
<td></td>
</tr>
<tr>
<td>HDAC and methyltransferase inhibitors</td>
<td></td>
</tr>
<tr>
<td>Novel antitumor agents</td>
<td></td>
</tr>
<tr>
<td>Novel targets and pathways</td>
<td></td>
</tr>
<tr>
<td>PI3K/AKT inhibitors</td>
<td></td>
</tr>
<tr>
<td>Proteasome inhibitors</td>
<td></td>
</tr>
<tr>
<td>Topoisomerase inhibitors</td>
<td></td>
</tr>
<tr>
<td>Tubulin agents</td>
<td></td>
</tr>
<tr>
<td>Tyrosine kinase and phosphatase inhibitors</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ET07</th>
<th>Biological Therapeutic Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>(See also CL06: Immunology; IM02: Preclinical Immunotherapy)</td>
<td></td>
</tr>
<tr>
<td>Antireceptors</td>
<td></td>
</tr>
<tr>
<td>Apoptosis: Therapeutic manipulation</td>
<td></td>
</tr>
<tr>
<td>Growth factor receptors and other surface antigens as targets for therapy</td>
<td></td>
</tr>
<tr>
<td>Oncogenes, tumor suppressor genes, and gene products as targets for therapy</td>
<td></td>
</tr>
<tr>
<td>Protein kinases and phosphatases as targets for therapy</td>
<td></td>
</tr>
<tr>
<td>Role of microenvironment in therapeutic response</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ET08</th>
<th>Gene and Vector-Based Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antisense molecules</td>
<td></td>
</tr>
<tr>
<td>Gene therapy and radiation studies</td>
<td></td>
</tr>
<tr>
<td>Immune modulators</td>
<td></td>
</tr>
<tr>
<td>Vector systems and targeting strategies</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ET09</th>
<th>Preclinical Radiotherapeutics</th>
</tr>
</thead>
<tbody>
<tr>
<td>(See also TB09: Radiation Science; CL07: Radiation Oncology)</td>
<td></td>
</tr>
<tr>
<td>Modification of radiosensitivity</td>
<td></td>
</tr>
<tr>
<td>Molecular targets of radiation response</td>
<td></td>
</tr>
<tr>
<td>Normal tissue/cellular stress responses to radiation</td>
<td></td>
</tr>
<tr>
<td>Radioprotectors and radiosensitizers</td>
<td></td>
</tr>
<tr>
<td>Radiotherapeutic combinations</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IM</th>
<th>Immunology</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM01</td>
<td>Tumor Immunobiology</td>
</tr>
<tr>
<td>Adaptive immunity in tumors</td>
<td></td>
</tr>
<tr>
<td>Epigenetic regulation of tumor immunity</td>
<td></td>
</tr>
<tr>
<td>Inflammation and cancer: Metastasis</td>
<td></td>
</tr>
<tr>
<td>Inflammation and cancer: Tumor initiation and progression</td>
<td></td>
</tr>
<tr>
<td>Innate immunity to tumors</td>
<td></td>
</tr>
<tr>
<td>Microbiome, inflammation, and cancer</td>
<td></td>
</tr>
<tr>
<td>Novel animal models</td>
<td></td>
</tr>
<tr>
<td>Oncogenic pathway-mediated regulation of inflammation and tumor immunity</td>
<td></td>
</tr>
<tr>
<td>Tumor antigenicity/processing and presentation</td>
<td></td>
</tr>
<tr>
<td>Tumor-induced immune suppression: Extrinsic factors</td>
<td></td>
</tr>
<tr>
<td>Tumor-induced immune suppression: Intrinsic factors</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IM02</th>
<th>Preclinical Immunotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>(See also CL06: Immunology; ET07: Biological Therapeutic Agents)</td>
<td></td>
</tr>
<tr>
<td>Adaptive cell therapy</td>
<td></td>
</tr>
<tr>
<td>Combination immunotherapies</td>
<td></td>
</tr>
<tr>
<td>Immune checkpoints</td>
<td></td>
</tr>
<tr>
<td>Immune mechanisms invoked by other therapies including chemotherapy</td>
<td></td>
</tr>
<tr>
<td>Immune mechanisms invoked by radiation therapy</td>
<td></td>
</tr>
<tr>
<td>Immune monitoring/clinical correlates</td>
<td></td>
</tr>
<tr>
<td>Immune response to therapies</td>
<td></td>
</tr>
<tr>
<td>Immunomodulatory agents and interventions</td>
<td></td>
</tr>
<tr>
<td>Inflammation, immunity, and cancer</td>
<td></td>
</tr>
<tr>
<td>Modifiers of the tumor microenvironment</td>
<td></td>
</tr>
<tr>
<td>Therapeutic antibodies, including engineered antibodies</td>
<td></td>
</tr>
<tr>
<td>Vaccines (oncolytic and prophylactic)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>
CT  Clinical Trials
All clinical trials should be submitted by the January 10, 2022 clinical trials abstract deadline.

CT01  Phase I Adult Clinical Trials
(See also CT05: Pharmacology, Pharmacogenomics, and Pharmacogenetics)

CT02  Phase II Adult Clinical Trials

CT03  Phase III Adult Clinical Trials

CT04  Phase I, II, or III Clinical Trials in Pediatric Cancer
(See also CT02: Pediatric Cancer – Clinical Investigations; TB08: Pediatric Cancer – Basic Science)

CT05  Phase I, II, or III Clinical Trials in the Elderly

CT06  Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations

CT07  COVID-19, Cancer, and Clinical Trials
(See also COVID01: COVID-19 and Cancer)

Phase I
Phase II
Phase III
Phase IV, observational, and expanded access
Clinical trials in progress

CT08  Clinical Trials in Progress
Phase I clinical trials in progress
Phase II clinical trials in progress
Phase III clinical trials in progress

CL  Clinical Research
[not including clinical trials; see also the Clinical Trials (CT) categories]

CL01  Translational Research – Molecular Biology in Clinical Oncology
(See also: TB07: In Vivo Imaging)
Clinical imaging
Cytogenetics and clinical molecular genetics
Epigenetic therapy
Functional and molecular imaging
Laboratory correlates for targeted agents
Molecular classification of tumors
Radiomics
Tumor staging: Correlation of clinical and molecular markers

CL02  Pediatric Cancer – Clinical Investigations
(See also CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB08: Pediatric Cancer – Basic Science)
Adolescent and young adult oncology
Childhood cancer drug development
Immunotherapeutic approaches to pediatric cancer
Pediatric cancer predisposition and surveillance
Survivorship, late effects, and second cancers
Therapeutic dosing, resistance, and combination therapy approaches in pediatric oncology
Translational pediatric cancer research

CL03  Clinical Research in the Elderly
Aging, immunity, and cancer

CL04  Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations
Biobanking/biopspecimen collection
Clinical trial design
Community-engaged research/community-based participatory research
Community outreach and patient accrual
Impact of COVID-19 on patient accrual

CL05  Biostatistics in Clinical Trials
Design and analysis of clinical trials
New study designs: Theory, methodology, and modeling
Statistical modeling for cancer studies

CL06  Immuno-oncology
(See also ET07: Biological Therapeutic Agents; IM02: Preclinical Immunotherapy)
Adaptive cell therapy
Combination immunotherapies
Immune checkpoints
Immune mechanisms involved in other therapies including chemotherapy
Immune mechanisms involved by radiation therapy
Immune monitoring/clinical correlates
Immune response to therapies
Immunomodulatory agents and interventions
Inflammation, immunity, and cancer
Modifiers of the tumor microenvironment
Therapeutic antibodies, including engineered antibodies
Vaccines (oncolytic and prophylactic)

CL07  Radiation Oncology
(See also TB09: Radiation Science; ET09: Preclinical Radiotherapeutics)
Clinical radiotherapeutic studies
Interventional radiology
Modification of radiosensitivity
Radiation-immunotherapy and other radiotherapeutic combinations
Radiation-induced late effects/second cancers
Radiation-induced resistance

CL08  Surgical Oncology (including Prophylactic Surgery)
Surgical oncology

CL09  Clinical Endocrinology
(See also EN01: Molecular, Preclinical, and Clinical Endocrinology)
Endocrine-related cancers
Hormone receptors and diagnosis/prognosis
Hormone signaling and inhibitors
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Steroid hormone receptors

CL10  Survivorship Research and Supportive Care
Biology of cell and tissue damage
Cardio-oncology
Comparative effectiveness research and cost-effective studies
Late effects of cancer and its treatment, including second cancers
Psycho-oncology
Supportive care, palliation, and pain management
Translational survivorship research

CL11  Biomarkers
Biomarkers predictive of therapeutic benefit
Diagnostic biomarkers
Early detection biomarkers
Liquid biopsies: Circulating DNA
Liquid biopsies: Circulating tumor cells
Metastasis biomarkers
Prognostic biomarkers
Spatial proteomics and transcriptomics

CL12  Clinical Outcomes Research
Clinical outcomes research

CL13  Real-World Data (RWD) and Real-World Evidence (RWE)
Analyses using clinico-genomic databases
Clinical informatics and data science
Retrospective clinical analyses

CL14  Precision Oncology
Combination therapy
Molecular targeted therapy

EN  Endocrinology

EN01  Molecular, Preclinical, and Clinical Endocrinology
(See also CL09: Clinical Endocrinology)
Endocrine-related cancers
Growth factors, receptors, and signal transduction
Hormone receptors and diagnosis/prognosis
Hormone signaling and inhibitors
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Steroid hormone receptors

CT  Clinical Trials
All clinical trials should be submitted by the January 10, 2022 clinical trials abstract deadline.

CT01  Phase I Adult Clinical Trials
(See also CT05: Pharmacology, Pharmacogenomics, and Pharmacogenetics)

CT02  Phase II Adult Clinical Trials

CT03  Phase III Adult Clinical Trials

CT04  Phase I, II, or III Clinical Trials in Pediatric Cancer
(See also CT02: Pediatric Cancer – Clinical Investigations; TB08: Pediatric Cancer – Basic Science)

CT05  Phase I, II, or III Clinical Trials in the Elderly

CT06  Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations

CT07  COVID-19, Cancer, and Clinical Trials
(See also COVID01: COVID-19 and Cancer)

Phase I
Phase II
Phase III
Phase IV, observational, and expanded access
Clinical trials in progress

CT08  Clinical Trials in Progress
Phase I clinical trials in progress
Phase II clinical trials in progress
Phase III clinical trials in progress
PS  Population Sciences

PS01  Population Sciences
Aging as a risk factor
Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects
Biomarkers of prognosis
Cancer health disparities research
Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends
Diet, alcohol, tobacco use, and other lifestyle risk factors
Environmental and occupational risk factors
Familial and hereditary cancers
Functional studies of genetic variants
Gene-gene and gene-environment interactions
Genome-wide association studies (GWAS)/post-GWAS
Health services and comparative effectiveness research
Infection and immune factors
Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)
Pathway and candidate gene studies of risk or prognosis
Pharmacopeidemiology
Preneoplastic and tumor markers
Primary and secondary intervention studies
Risk prediction models for incidence, prognosis, and/or mortality
Screening and early detection
Statistical and epidemiological methodology
Survivorship research
Other

PR  Prevention, Early Detection, and Interception

PR01  Preclinical Prevention, Early Detection, and Interception
Animal models in prevention
Biological and biochemical mechanisms in prevention
Biomarkers and intervention studies
Cellular models
Chemoprevention studies
Diet, nutrition, and cancer
Molecular markers in prevention research
New agent development
Screening and early detection
Other

PR02  Clinical Prevention, Early Detection, and Interception
Application of molecular pathology in clinical prevention
Biomarkers and intervention studies
Cancer health disparities research
Cancer surveillance and screening studies
Chromoprevention clinical trials
Genetic markers as surrogate endpoints in prevention trials
Genomics and proteomics in cancer risk and response assessment
Infections and virus-related cancers
Microbiome and prevention
Prevention and treatment of premalignant lesions (intraepithelial neoplasia)
Prevention of second cancers
Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials
Screening and early detection
Other

PR03  Implementation Science
Behavioral science and prevention
Cancer communication and decision-making
Cancer health disparities research
Genetic testing and counseling
Health policy and outcomes
Obesity, diet, physical activity, and energy balance
Quality of life/late effects/survivorship
Other

COVID  COVID-19 and Cancer

COVID01  COVID-19 and Cancer
Cancer drug repurposing to treat COVID-19
Cancer prevention and early detection during the COVID-19 pandemic
Clinical trials (See also CT07: COVID-19, Cancer, and Clinical Trials (Phase I–Phase IV and Trials in Progress))
Continuity of cancer care
COVID-19 vaccine development
COVID-19 vaccines and immune responses among cancer patients
Diagnostics for COVID-19 testing: Design, development, and validation
Effects of cancer immunotherapies on patients with COVID-19 (with or without cancer)
Effects of COVID-19 on cancer survivorship
Epidemiology and registries of COVID-19 and cancer (including biorepositories)
Health inequities and disparities during the COVID-19 pandemic
Intersection of the biology of SARS-CoV-2 and cancer
Risk factors and comorbidities resulting in adverse outcomes for cancer patients with COVID-19
Science and public policy
Other

RSP  Regulatory Science and Policy

RSP01  Regulatory Science and Policy
Biosimilars and generics
Clinical trial design and accrual
Combination therapies and codevelopment of investigational agents and diagnostics
Data science and informatics
Novel endpoints and biomarkers
Real-world evidence and retrospective analyses
Tobacco and e-cigarette regulation
Other

SHP  Science and Health Policy

SHP01  Science and Health Policy
Cancer health disparities
Cancer survivorship
Comparative effectiveness research
Implementation science
Patient advocacy and engagement
Value and cost issues in cancer care
Other
AACR Membership: The Essential Association for You

With over 48,000 members in 127 countries and territories around the world, the AACR is a dynamic and vibrant organization that offers its members opportunities to participate more fully in the global initiative to eliminate cancer. AACR membership is available to both senior and early-career investigators who conduct cancer research and related biomedical science, as well as to those health care professionals, research administrators, cancer survivors and advocates, students, and others who share the AACR’s vision and support our mission to prevent and cure cancer.

AACR membership categories promote the professional growth of those in training, facilitate collaborations for established scientists, and provide support for all working in cancer research. Special rates are available to members located in countries with emerging economies as designated by the World Bank. For a complete list of countries with emerging economies, please visit AACR.org/International.

Membership Application Deadlines for Abstract Sponsorship

AACR members have the exclusive benefit of being able to sponsor and endorse abstracts for presentation at the AACR Annual Meeting. Members must be in good standing (dues paid or eligibility recertified) in order to take advantage of this member privilege. (Refer to page 24 for full details and instructions on sponsoring an abstract.)

Nonmember individuals interested in joining the AACR and sponsoring an abstract must submit an application for membership no later than November 12, 2021. Individuals interested in joining the AACR and sponsoring a late-breaking abstract must submit an application for membership no later than January 5, 2022.
Abstract Sponsorship

Membership Application
Deadlines
November 12, 2021
January 5, 2022

Abstract Submission
Deadlines
November 18, 2021
January 10, 2022
(Late-Breaking and Clinical Trials)

Scholar Awards

Membership Application
Deadline
November 12, 2021

All Travel Awards
Application Deadline
November 18, 2021

Contact the AACR Membership Department with any questions at 215-440-9300 or membership@aacr.org.

AACR Membership Categories

Active Membership is open to investigators worldwide who have established a record of scholarly activity resulting in original peer-reviewed articles in publications relevant to cancer research and biomedical science.

Affiliate Membership is open to qualified individuals who are health professionals working in support of cancer research and biomedical science; survivors and advocates who are members of organizations whose mission includes the advancement of cancer research; educators; or other professionals who are interested in and/or make substantial contributions to the cancer field.

Associate Membership is open to graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to careers in cancer research and the related sciences. Annual dues are not required. (Important reminder: Beginning in 2021, Associate members are required to recertify their eligibility in order to remain on the member rolls. Please log in to myAACR to retain your member-exclusive benefits!)

Student Membership is open to persons who have manifested an interest in cancer and the related biomedical sciences and who are enrolled in a program leading to a high school diploma or a bachelor’s degree. Annual dues are not required.

Sustaining Membership is open to organizations in recognition of annual payment of dues and other substantial contributions in support of the mission, purposes, and activities of the AACR. Annual dues are determined by the Sustaining Member level.

Emeritus Membership is open to existing Active Members who have reached the age of 70 years, who are disabled, or who are retired.

Honorary Membership is open to distinguished individuals who have made extraordinary contributions to the advancement of cancer research either through outstanding personal scientific activity or through exceptional leadership in cancer research. (Candidates for Honorary Membership are invited through a special selection process.)

Please contact the Membership Department at membership@aacr.org or 215-440-9300 and a membership representative will gladly assist with any questions. Not yet a member? Apply for membership at myAACR and join us in the global conquest of cancer.

Supporting Diversity, Equity, and Inclusion

The AACR strives to support the professional development and career advancement of underrepresented minority and women scientists in cancer research. Through the efforts of AACR-Minorities and Cancer Research and AACR-Women in Cancer Research, the AACR is working to increase the number, participation, visibility, and recognition of investigators through various initiatives.

AACR-Minorities in Cancer Research (MICR)

Minorities in Cancer Research (MICR) is a membership group within the AACR committed to preventing and curing cancer and eradicating cancer health disparities while meeting the professional needs and advancing the careers of minority scientists. It is led by the MICR Council, which is the advisory body to the AACR leadership on issues of concern to minority investigators and is also responsible for spearheading initiatives and organizing activities of MICR through its committees.

MICR will present several exciting and engaging activities during the AACR Annual Meeting, including:

• MICR Networking and Resource Center. The MICR Networking and Resource Center provides meeting attendees with a comfortable environment to network one-on-one and in small groups while learning about AACR and MICR programs as well as MICR membership and committee service opportunities.
• **Scientific Symposium.** This session informs the cancer research community about cancer issues related to race and ethnicity and provides a platform for minority scientists to present their work with discussion.

• **Forum.** This session provides useful tools and information to support the professional development of minority cancer researchers.

• **MICR Town Hall.** This session provides an opportunity for all attendees who support MICR to join in the MICR Council in an informal discussion about current topics that have an impact on the cancer community and underrepresented minorities.

• **MICR Meet and Greet.** All AACR Annual Meeting attendees are invited to informally network with the MICR Council, Committee Members, and Scholar Awardees for one on one or group discussions.

• **Scholar Award Programs.** Focuses on underrepresented minority early-career researchers and faculty, as well as faculty at Minority-Serving Institutions.

All AACR Annual Meeting attendees and MICR members are invited to learn more about MICR programs, committees, and other programs of interest by visiting [AACR.org/MICR](http://AACR.org/MICR) or emailing micr@aacr.org. Nonmembers are welcome to visit and join.

### Women in Cancer Research

Women in Cancer Research (WICR) is a membership group within the AACR committed to recognizing women’s scientific achievements and fostering their career development and advancement in cancer research. It is led by the WICR Council, the advisory body to the AACR leadership on issues of concern to women investigators which is also responsible for organizing the activities of WICR through its committees.

Activities taking place during the Annual Meeting:

• **Forum.** This session provides useful tools and information to support the professional development of women investigators.

• **WICR Networking and Resource Center.** The WICR Networking and Resource Center provides meeting attendees with a comfortable environment to network one-on-one and in small groups while learning about AACR and WICR programs as well as WICR membership and committee service opportunities.

All AACR Annual Meeting attendees and WICR members are invited to learn more about WICR programs, committees, and other programs of interest by visiting [AACR.org/WICR](http://AACR.org/WICR) or emailing wicr@aacr.org. Nonmembers are welcome to visit and join.

### 17th Annual Undergraduate Student Caucus and Poster Competition

With more than 250 undergraduate student participants every year, the AACR Undergraduate Student Caucus and Poster Competition continues to be the premier event for undergraduate students attending the AACR Annual Meeting. Now in its 17th year, this program provides undergraduate students with the opportunity to learn more about current research in the cancer field, hear from investigators about educational pathways and career development, explore career options in the cancer field, and compete for the Margaret Foti Foundation Undergraduate Prizes for Cancer Research while presenting research. Undergraduates at all levels are welcome to participate in this highly anticipated program without cost. To learn more about this exciting opportunity, please visit [AACR.org/ScienceEducation](http://AACR.org/ScienceEducation) or send an email to scienceeducation@aacr.org.

**Abstract Submission Deadline:** February 11, 2022  
**Registration Deadline:** March 18, 2022

### Supporting AACR Associate Members (Early-Career Researchers/Scientists)

With over 23,000 Associate members in the AACR, the AACR supports the education, training, and professional development of early-career researchers/scientists, who are graduate students, medical students and residents, and clinical and postdoctoral fellows, in the cancer field.

The AACR Associate Member Council (AMC) are Associate members of the AACR who are elected to serve as an advisory body to the AACR leadership and to address the needs and concerns of early-career researchers/scientists. The AMC works to support the AACR’s mission to prevent and cure cancer by promoting the professional development of early-career researchers/scientists throughout the world and encouraging Associate member recruitment, retention, and engagement.
Opportunities for Associate Members During the AACR Annual Meeting

Some key AACR Annual Meeting programs for Associate members include the Professional Advancement Series Sessions, special sessions featuring AACR senior scientists and recently transitioned early-stage cancer investigators, and more. Below are additional opportunities for Associate members taking place during the AACR Annual Meeting.

• **Career Discussions.** Organized by the AMC, these informal networking and discussion sessions are designed for early-career researchers to interact with recently transitioned physician-scientist and junior faculty/equivalent peers around various career topics.

• **Associate Member Meet and Greet.** Hosted by the AMC, Associate members are able to meet and network with other early-career attendees and Council members.

• **Recognition and Scholar Awards.** The AACR offers several scholar awards to meritorious early-career researchers residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Please refer to pages 19-20.

AACR Member Exclusive Benefit

**Early Access to AACR Annual Meeting Housing Reservations**

Tuesday, September 21, 2021 (opens at 9:00 a.m. U.S. ET) through Monday, September 27, 2021 at 11:59 p.m. (U.S. ET)

As a member exclusive benefit, AACR members in good standing (dues paid through December 31, 2021) are eligible to reserve hotel accommodations for the AACR Annual Meeting 2022 before reservations open to all attendees. Members may log on to myAACR to check dues status and make a payment using the secure AACR site.

“**The meeting exposed me to cutting-edge research topics in cancer.**”
Hotel Reservations

CMR (Convention Management Resources) is the official hotel management company for the AACR Annual Meeting.

Hotel reservations for the AACR Annual Meeting 2022 will open at 9:00 a.m. U.S. ET on Tuesday, September 21, 2021, for all AACR members in good standing. Housing for nonmember attendees will open at 9:00 a.m. on Tuesday, September 28, 2021. The deadline for making hotel reservations is Friday, February 25, 2022. After the deadline, registrants may be required to make their own housing arrangements.

You may reserve your hotel room in one of the following ways:

Online: Visit the AACR Annual Meeting website at AACR.org/AACR2022 to reserve your hotel room online. Please note that you must supply a credit card in order to reserve a room online. You will find descriptions, amenity information, and photographs for each AACR official hotel. Additionally, a map showing the location of all hotels and the New Orleans Ernest N. Morial Convention Center is available on the AACR Housing website. Visit the AACR Housing website to get up-to-the-minute availability and receive immediate confirmation of your hotel reservation.

Phone: AACR Housing agents will be available to accept reservations as well as provide information on the official AACR hotels Monday through Friday from 9:00 a.m. to 9:00 p.m. U.S. ET. You will be required to supply a credit card if you reserve your hotel room by phone. Once your reservation is complete, you will receive immediate confirmation by email. AACR Housing can be reached toll-free in the U.S. and Canada at 888-381-7166 or for international callers at 415-979-2262. When calling AACR Housing be certain to have the following information:

- Arrival and departure dates
- Hotel preferences
- Credit card number
- Your address, phone number, fax number, and email address
- Any special requests
Guarantee

Reservations must be guaranteed with either a major credit card (AMEX, Visa, or MasterCard) or a check in the amount of $300 per guestroom and $700 per suite. Make checks payable to Convention Management Resources, Inc. If using a credit card, the card will not be charged until the check-out date. You must present a credit card upon check-in.

Changes and Cancellations

Changes and cancellations can be made:

- Online at the AACR Housing website at [AACR.org/AACR2022](http://AACR.org/AACR2022)
- By emailing your change or cancellation to AACRSupport@cmrus.com
- By calling AACR Housing at 888-381-7166 or 415-979-2262
- By faxing your change or cancellation to 415-293-4397

Your credit card will be charged one night’s room plus tax or your check deposit will be forfeited if you cancel your reservation less than 72 hours before your confirmed arrival date. If you fail to arrive on the date confirmed by AACR Housing, your credit card will be charged one night’s room plus tax or your check will be forfeited. All subsequent nights of the reservation will be cancelled.

Hospitality Suites

Suites are for sleeping accommodation only and may not be used for meetings or events without prior written permission from AACR. For these types of events, please complete the AACR Affiliate Event Space Request Form. If you would like a copy of this form, please contact AACR Housing at 888-381-7166, 415-979-2262, or via email at AACRSupport@cmrus.com.

Group Reservations

Organizations wishing to hold a block of rooms must use the Group Housing Form, which can be obtained by visiting [AACR.org/AACR2022](http://AACR.org/AACR2022) and clicking on the Housing link. Exhibitors may request rooms in the AACR room block and must submit an Exhibitor Room Block Request Form, which can be accessed from [AACR.org/AACR2022](http://AACR.org/AACR2022). Please adhere to all rules and regulations to facilitate processing. Confirmation will be emailed.

The AACR is aware that one or more unauthorized companies are using deceptive advertising methods to direct users to fraudulent websites that purport to offer housing and registration for the AACR Annual Meeting 2022. Please note that [AACR.org/AACR2022](http://AACR.org/AACR2022) is the only website through which users can register to attend the AACR Annual Meeting and confirm a hotel room. AACR cannot guarantee your registration or housing if you purchase using an illegitimate website.
Air Transportation

The Louis Armstrong New Orleans International Airport (airport code: MSY) is the major airport in the New Orleans Region and offers multiple U.S. and international flights daily. New Orleans is also served by Amtrak.

Travel Office  ➤ Corporate Traveler

Phone: 215-825-3650
Toll-Free: +1-888-666-4209
Email: Samantha.baron@corporatetraveler.us
$30 service fee applies
Business hours: Monday-Friday, 8:00 a.m. to 6:00 p.m. ET

Assistance for International Travelers

An official letter of invitation is available through the online registration system. Contact the American Consulate in your country to review the current regulations for travel to the United States. Please begin the visa application process as early as possible. Information is available on the U.S. Department of State website at www.travel.state.gov.

Ground Transportation

Taxi Service

Louis Armstrong New Orleans International Airport is located 11 miles from downtown New Orleans. Many companies provide taxicab service at Louis Armstrong New Orleans International Airport. If you need a taxi, simply follow the signs leading to the Transportation Plazas. A customer service representative will place you with the first available taxi, unless you specify a particular taxicab company.
Public Transportation

New Orleans Regional Transit Authority (RTA) buses and streetcars wind through every neighborhood of the Crescent City. To see RTA fare and pass options, visit AACR.org/RTA.

Four streetcar lines run through some of the most iconic areas of New Orleans—the historic St. Charles Avenue line, the Canal Street line to Cemeteries and City Park, the Riverfront line, and the newest line, the Rampart-St. Claude Avenue line.

The Paratransit option is a shared ride service designed to help customers who are unable to use regular transit services due to a disability or disabling health condition.

Jefferson Transit (JeT) and St. Bernard Parish Rapid Urban Transit (SBURT) are public transit systems that operate independently of the RTA. Riders can transfer to either system or into the RTA system from either system. RTA, JeT, and SBURT all have separate fare and pass options that are not transferable to other systems. To see JeT fare and pass options, visit AACR.org/JeT. To see SBURT fare and pass options, visit AACR.org/SBURT.

Airport Shuttle

The Airport Shuttle is the official ground transportation for the Louis Armstrong New Orleans International Airport. Look for Airport Shuttle signage right outside the baggage area. The vehicles are white with yellow “Airport Shuttle” lettering on the side.

Airport Shuttle service is available to and from Downtown and Uptown New Orleans hotels, the French Quarter, the Ernest N. Morial Convention Center and the Cruise Ship Terminals.

Look for the Airport Shuttle parked in front of your hotel/departure location approximately 5 to 7 minutes before scheduled departure time. Shuttles run every day of the year, with vans departing approximately every 30 minutes (except between 2:00 a.m. and 3:30 a.m.).

You can purchase ticket(s) at www.airportshuttleneworleans.com or in person at the Airport Shuttle Ticket Desk, located on the ground level of the airport across from the baggage claim area, or you can make a reservation by calling 866-596-2699. For Departure Reservations (from downtown New Orleans back to the airport), please call 504-522-3500 or 866-596-2699 no later than 24 hours prior to your flight.

“Format of the meeting again worked beautifully! Presenters were engaging and topics of discussion and sessions were all highly relevant and informative.”

TMS Shuttle Service

The AACR will provide complimentary shuttle service for all official AACR Annual Meeting hotels that are not within walking distance to the Ernest N. Morial Convention Center. When available, the hotel shuttle schedule will be posted on AACR.org/Travel and will include shuttle hours of operation and the designated route number for each hotel.
Opportunities to Support the AACR Foundation

The AACR Foundation welcomes support from corporations, foundations, individuals, and other organizations that share its mission and are interested in helping to defray the costs of presenting this important international meeting on the latest developments in cancer research. For a complete list of support opportunities and their many benefits, please contact Peter VanPelt, Senior Director of Development, at 215-446-7256 or via email at peter.vanpelt@aacr.org.

Fellows of the AACR Academy

The AACR Academy was established in 2013 to honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. Those elected, known as Fellows of the AACR Academy, constitute a global brain trust of individuals who are instrumental in advancing the mission of the AACR to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

The AACR Academy is currently led by Dr. Charles L. Sawyers (2021-2023 AACR Academy President) and a Steering Committee of additional Fellows who serve as the collective voice for all Fellows of the AACR Academy, while providing ongoing advice and counsel to the AACR leadership on timely and significant scientific and policy topics as well as other matters of importance to the cancer field.

The next elected class of prestigious Fellows of the AACR Academy will be formally recognized in conjunction with the AACR Annual Meeting 2022 Opening Ceremony, scheduled to take place on Sunday, April 10.

AACR Scientific Achievement Awards, Lectureships, and Prizes

Since 1961, the AACR has been proud to recognize scientific excellence across the spectrum of basic, translational, clinical, and epidemiological cancer research through a robust collection of annual awards and lectureships that serve to honor laboratory researchers, physician-scientists, and population scientists who have made significant contributions to our understanding of the diagnosis, prevention, and treatment of cancer. All annual award recipients are honored during the AACR Annual Meeting and the
majority are invited to present featured lectures in conjunction with the meeting.

Please find listed below, all upcoming nomination submission deadlines and a complete listing of all 2022 awards. Visit AACR.org/Awards to learn more and to nominate your colleagues!

**Nomination Submission Deadline: Thursday, September 30**
- AACR Award for Lifetime Achievement in Cancer Research
- AACR Award for Outstanding Achievement in Basic Cancer Research
- AACR Award for Outstanding Achievement in Blood Cancer Research – **New for 2022!**
- AACR Award for Outstanding Achievement in Chemistry in Cancer Research
- AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
- AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
- AACR Team Science Award
- AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
- AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
- AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research
- AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research
- AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship
- AACR-Princess Takamatsu Memorial Lectureship
- AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research
- AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research
- AACR-Women in Cancer Research Charlotte Friend Lectureship
- Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

**Nomination Submission Deadline: Friday, December 31**

**New for 2022!**
- AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research

**Registration**

The health and safety of AACR Annual Meeting attendees, as well as the patients and communities they serve, remain the AACR’s highest priorities. Therefore, the AACR will be requiring proof of COVID-19 vaccination for all attendees. Online registration for the AACR Annual Meeting 2022 will open in October 2021. At that time, a complete list of registration options and rates—as well as details on the vaccination verification process—will be posted to the AACR website at AACR.org/AACR2022.

**Exhibit Show**

The 2022 AACR Exhibits Show will include a wide array of companies with the latest products and services for laboratory and clinical research. Additional areas of interest include Publisher’s Row, AACR Advocacy Partners’ Pavilion, Exhibitor Spotlight Theaters, and AACR Central. If your organization would like to exhibit please contact the Exhibits Team at exhibits@aacr.org.

**About New Orleans**

New Orleans is a unique destination with a vibrant culture and way of life that started over 300 years ago and continues to flourish today. America’s most authentic city welcomed more than 18.5 million visitors in 2018. Cvent named New Orleans among the “Top 50 Meeting Destinations in the United States” six years in a row. Enjoy the world-renowned cuisine, the rich melting pot of musical heritage, and the warm, friendly people who make this revitalized city a memorable experience. With more than 22,000 hotel rooms within the downtown area, as well as many other venues and attractions, New Orleans is one of the most walkable cities in the country. Visitors can walk out of their hotel rooms and are only a short stroll away from the Garden District, French Quarter, and the exciting Warehouse District, which is conveniently located by the convention center. Experience the World War II Museum (part of the Smithsonian family of museums), the New Orleans Museum of Art, the New Orleans Aquarium, and the many galleries throughout the city exhibiting local artists’ work. Choose from over 1,500 restaurants that define the city as a top “foodies” destination.
## HOTEL LIST

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Rate</th>
<th>Hotel</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Hilton New Orleans Riverside (HQ Hotel)</td>
<td>$269.00</td>
<td>9 Courtyard New Orleans</td>
<td>$225.00</td>
</tr>
<tr>
<td>2 Poydras Street</td>
<td></td>
<td>Downtown/Convention Center</td>
<td></td>
</tr>
<tr>
<td>2 New Orleans Marriott (CO-HQ Hotel)</td>
<td>$265.00</td>
<td>10 Courtyard New Orleans</td>
<td>$235.00</td>
</tr>
<tr>
<td>555 Canal Street</td>
<td></td>
<td>French Quarter/Iberville</td>
<td></td>
</tr>
<tr>
<td>3 Sheraton New Orleans Hotel (CO-HQ Hotel)</td>
<td>$259.00</td>
<td>11 Crowne Plaza New Orleans</td>
<td>$239.00</td>
</tr>
<tr>
<td>500 Canal Street</td>
<td></td>
<td>French Quarter</td>
<td></td>
</tr>
<tr>
<td>4 AC Hotel New Orleans Bourbon French Quarter</td>
<td>$209.00</td>
<td>12 DoubleTree Hotel New Orleans</td>
<td>$230.00</td>
</tr>
<tr>
<td>221 Carondelet Street</td>
<td></td>
<td>Convention Center</td>
<td></td>
</tr>
<tr>
<td>5 Aloft New Orleans Downtown</td>
<td>$189.00</td>
<td>13 Eliza Jane</td>
<td>$254.00</td>
</tr>
<tr>
<td>225 Baronne Street</td>
<td></td>
<td>315 Magazine Street</td>
<td></td>
</tr>
<tr>
<td>6 Blake Hotel New Orleans</td>
<td>$199.00</td>
<td>14 Embassy Suites New Orleans -</td>
<td>$243.00</td>
</tr>
<tr>
<td>500 St. Charles Avenue</td>
<td></td>
<td>Convention Center</td>
<td></td>
</tr>
<tr>
<td>7 Cambria Hotel &amp; Suites</td>
<td>$219.00</td>
<td>15 Hampton Inn &amp; Suites</td>
<td>$259.00</td>
</tr>
<tr>
<td>Downtown Warehouse District</td>
<td></td>
<td>New Orleans Convention Center</td>
<td></td>
</tr>
<tr>
<td>632 Tchoupitoulas Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Courtyard New Orleans Downtown</td>
<td>$215.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>124 St. Charles Avenue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Courtyard New Orleans Downtown</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Courtyard New Orleans</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>300 Julia Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Crowne Plaza New Orleans</td>
<td>$239.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>739 Canal Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Crowne Plaza New Orleans</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>910 Iberville Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 DoubleTree Hotel New Orleans</td>
<td>$230.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>300 Canal Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 Eliza Jane</td>
<td>$254.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>315 Magazine Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 Embassy Suites New Orleans -</td>
<td>$243.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>315 Julia Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 Hampton Inn &amp; Suites</td>
<td>$259.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Orleans Convention Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotel</td>
<td>Rate</td>
<td>Hotel</td>
<td>Rate</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>-------</td>
<td>--------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Hampton Inn &amp; Suites</td>
<td>$205.00</td>
<td>Old No. 77 Hotel</td>
<td>$209.00</td>
</tr>
<tr>
<td>New Orleans Downtown/French Quarter Area</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>226 Carondelet Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Higgins Hotel New Orleans, Curio Collection by Hilton</td>
<td>$249.00</td>
<td>Omni Riverfront Hotel</td>
<td>$259.00</td>
</tr>
<tr>
<td>1000 Magazine Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hilton Garden Inn</td>
<td>$225.00</td>
<td>Q&amp;C Hotel/Bar</td>
<td>$229.00</td>
</tr>
<tr>
<td>New Orleans Convention Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1001 South Peters Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hilton Garden Inn</td>
<td>$189.00</td>
<td>Renaissance New Orleans</td>
<td>$249.00</td>
</tr>
<tr>
<td>New Orleans French Quarter/CBD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>821 Gravier Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hilton New Orleans/St. Charles Avenue</td>
<td>$239.00</td>
<td>Renaissance Pere Marquette</td>
<td>$249.00</td>
</tr>
<tr>
<td>333 St. Charles Avenue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homewood Suites by Hilton</td>
<td>$199.00</td>
<td>Residence Inn New Orleans</td>
<td>$239.00</td>
</tr>
<tr>
<td>New Orleans French Quarter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>317 North Rampart Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotel Monteleone</td>
<td>$245.00</td>
<td>Royal Sonesta New Orleans</td>
<td>$235.00</td>
</tr>
<tr>
<td>214 Royal Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyatt Centric French Quarter New Orleans</td>
<td>$249.00</td>
<td>Sonesta ES Suites Convention Center</td>
<td>$225.00</td>
</tr>
<tr>
<td>800 Iberville Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyatt Place New Orleans/Convention Center</td>
<td>$229.00</td>
<td>SpringHill Suites New Orleans</td>
<td>$229.00</td>
</tr>
<tr>
<td>881 Convention Center Boulevard</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>InterContinental New Orleans</td>
<td>$249.00</td>
<td>St. James Hotel</td>
<td>$209.00</td>
</tr>
<tr>
<td>444 St. Charles Avenue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>International House Hotel</td>
<td>$229.00</td>
<td>Westin New Orleans</td>
<td>$259.00</td>
</tr>
<tr>
<td>221 Camp Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JW Marriott Hotel New Orleans</td>
<td>$269.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>614 Canal Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kimpton Hotel Fontenet</td>
<td>$235.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>501 Tchoupitoulas Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>La Quinta Inn &amp; Suites</td>
<td>$189.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Orleans Downtown</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>301 Camp Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Le Meridien New Orleans</td>
<td>$255.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>333 Poydras Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loews New Orleans</td>
<td>$259.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>300 Poydras Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnolia New Orleans</td>
<td>$229.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>535 Gravier Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Orleans Marriott</td>
<td>$269.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warehouse Arts District</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>859 Convention Center Boulevard</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The AACR is aware that one or more unauthorized companies are using deceptive advertising methods to direct users to fraudulent websites that purport to offer housing and registration for the AACR Annual Meeting 2022. Please note that AACR.org/AACR2022 is the only website through which users can register to attend the AACR Annual Meeting and confirm a hotel room. AACR cannot guarantee your registration or housing if you purchase using an illegitimate website.
AACR Annual Meeting Program Committee

**Chair**
Marcia R. Cruz-Correa

**Vice Chairs**
Sarah-Jane Dawson
Kojo Elenitoba-Johnson
Daniel Gomez
Roy S. Herbst
Helen E. Heslop
Katherine A. Janeway
Carl H. June
Miriam Merad
Augusto C. Ochoa
Woong-Yang Park
Varda Rotter

**Co-chairs**
Julie R. Brahmer
Jennifer A. Doherty
Jeffrey A. Engelman
Claudia Fischbach
Gregory R. Friberg
Kevin L. Gardner
Robert A. Gatenby
Masanori Hatakeyama
Trey Ideker
Catriona H.M. Jamieson
Philip Jones

Yu Shyr
Mariana Carla Stern
Danny R. Welch
Cheryl L. Willman
Timothy A. Yap

Beth Y. Karlan
Edison T. Liu
Ghecemy Lopez
Beth A. McCormick
Nicholas McGranahan
Ruben A. Mesa
William Pao
Kornelia Polyak
Martine Roussel
Anil K. Rustgi
Barbara Segarra-Vázquez
Lillian L. Siu
Julie Sutcliffe
Bin Tean Teh
Hongyang Wang
Clayton C. Yates
AACR ANNUAL MEETING COMMITTEES (cont’d)

AACR Annual Meeting Clinical Trials Committee

Co-chairs
Julie R. Brahmer
Timothy A. Yap

Members
Benedito A. Carneiro
Ezra E.W. Cohen
Marina Chiara Garassino
Marcus DaSilva Goncalves
Wendy B. London
Katherine K. Matthay
Edith P. Mitchell
Martine J. Piccart
Katy Rezvani
Stefania Scala
Naoko Takebe
Beverly A. Teicher
Margaret A. Tempero
Colin D. Weekes
Evan Y. Yu

Additional Appointments Pending

AACR Annual Meeting Education Committee

Chair
Lillian L. Siu

Co-chairs
Trey Ideker
Martine Roussel
Mariana Carla Stern

Members
Rima S. Al-awar
Adriana Albini
Nina Bhardwaj
Nadine J. Barrett
Ranjit S. Bindra
Gautam Borthakur
Lisa M. Coussens
Daniel D. De Carvalho
Marcia C. Haigis
Pasi A. Jänne
Giedre Krenciute
Karen T. Liby
Massimo Loda
Sherene Loi

Christine M. Lovly
Shiva Malek
Martin McMahon
Atsushi Ohtsu
Klaus Pantel
Martin G. Pomper
Camille C.R. Ragin
Renee Reams
Chris Sander
Sohrab Shah
Gregory H. Sonnenberg
Jennifer Tsui
Victor E. Velculescu
Jovanny Zabalta
Jinghui Zhang

AACR Exhibits Committee

Chair
Edward Chu

Members
Elana J. Fertig
Ajay Goel
Esther A. Obeng
Feyruz V. Rassool
Goli Samimi
Gina M. Sizemore
Rachel M. Syme
Ruoning Wang
Iain D.G. Watson

Additional Appointments Pending

AACR Continuing Medical Education Committee

Chair
Steven T. Rosen

Members
Sarki A. Abdulkadir
Karen A. Gelmon
Daniel A. Laheru
Bora Lim
Edith P. Mitchell
Jean L. Nakamura
Ruth M. O’Regan
Mark E. Robson
Anita Villani

Additional Appointments Pending

AACR Satellite Educational Symposia Committee

Appointments Pending

“...The meeting’s educational sessions have been essential to my career...”